Citadel Advisors’s Akoya BioSciences AKYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-100,467
| Closed | -$131K | – | 12665 |
|
|
2025
Q2 | $131K | Buy |
+100,467
| New | +$121K | ﹤0.01% | 11088 |
|
|
2025
Q1 | – | Sell |
-19,044
| Closed | -$41.7K | – | 14396 |
|
|
2024
Q4 | $43.6K | Sell |
19,044
-32,754
| -63% | -$86.8K | ﹤0.01% | 12536 |
|
|
2024
Q3 | $141K | Buy |
51,798
+44,026
| +566% | +$108K | ﹤0.01% | 10647 |
|
|
2024
Q2 | $18.2K | Sell |
7,772
-52,826
| -87% | -$168K | ﹤0.01% | 12725 |
|
|
2024
Q1 | $284K | Buy |
60,598
+47,200
| +352% | +$245K | ﹤0.01% | 9569 |
|
|
2023
Q4 | $65.4K | Sell |
13,398
-70,577
| -84% | -$293K | ﹤0.01% | 11476 |
|
|
2023
Q3 | $390K | Sell |
83,975
-39,283
| -32% | -$226K | ﹤0.01% | 8609 |
|
|
2023
Q2 | $911K | Buy |
123,258
+25,816
| +26% | +$172K | ﹤0.01% | 6653 |
|
|
2023
Q1 | $797K | Sell |
97,442
-41,787
| -30% | -$437K | ﹤0.01% | 7289 |
|
|
2022
Q4 | $1.33M | Buy |
+139,229
| New | +$1.71M | ﹤0.01% | 6265 |
|
|
2022
Q3 | – | Sell |
-28,230
| Closed | -$363K | – | 12522 |
|
|
2022
Q2 | $363K | Buy |
+28,230
| New | +$293K | ﹤0.01% | 9375 |
|
|
2022
Q1 | – | Sell |
-19,651
| Closed | -$228K | – | 13486 |
|
|
2021
Q4 | $301K | Sell |
19,651
-24,188
| -55% | -$316K | ﹤0.01% | 10913 |
|
|
2021
Q3 | $612K | Sell |
43,839
-1,822
| -4% | -$30.5K | ﹤0.01% | 9380 |
|
|
2021
Q2 | $883K | Buy |
+45,661
| New | +$943K | ﹤0.01% | 8676 |
|
Citadel Advisors's AKYA Position: Q3 2025 in Review
Citadel Advisors sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 100,467 shares — an estimated $131K sold.
Citadel Advisors first reported a position in AKYA in Q2 2021 and held it in 14 quarters. The position peaked at $1.33M in Q4 2022. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.
- Citadel Advisors reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 100,467 Akoya BioSciences shares in Q3 2025, an estimated $131K.
- Citadel Advisors first reported a position in Akoya BioSciences in Q2 2021 and held it in 14 quarters.
- Citadel Advisors's Akoya BioSciences position peaked at $1.33M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.